
During the development of cancer, cells frequently lose attributes of their tissue of origin and acquire some of the characteristics of stem cells, a process termed anaplasia. The aim of the research in our lab is to use stem cells to model the processes underlying cancer and to uncover the roles that novel stem cell and reprogramming factors play in the development of the disease. Using embryonic stem (ES) cells we are developing and improving models of human cancer. The targeted genetic modification of such cells allows us to study genes involved in cancer in fine detail so as to better understand their normal function and how these functions are compromised during the development of cancer.
Once modified ES cell lines are established, not only can gene function be analysed in the stem cells themselves but these cells can be differentiated into a wide variety of different cell types to allow the study of basic disease mechanisms in different tissues and potentially to establish screens for drug discovery.
In addition, it is possible to reverse the differentiation process and reprogramme a variety of somatic cells to induced pluripotential stem (iPS) cells. This process is reminiscent of anaplasia, the loss of differentiation seen in cancer. Genes crucial for this type of reprogramming are often involved in cancer development.
Email:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Lab Report
Scientific Report 2010 Strathdee
Key Publications
Strathdee D, Whitelaw CB, Clark AJ (2008). Distal transgene insertion affects CpG island maintenance during differentiation. J Biol Chem. 283, 11509-15.
Strathdee D, Ibbotson H, Grant SG (2006). Expression of transgenes targeted to the Gt(ROSA)26Sor locus is orientation dependent. PLoS One 1, e4.
Brown K, Strathdee D, Bryson S, Lambie W, Balmain A (1998). The malignant capacity of skin tumours induced by expression of a mutant H-ras transgene depends on the cell type targeted. Curr Biol. 8, 516-24.
Biography
Education and qualifications
1995: PhD, University of Glasgow, Supervisor Allan Balmain
1989: BSc, Immunology (Honours), University of Glasgow
Appointments
2009-present: Head of Transgenic Technology, Beatson Institute for Cancer Research
2004-2009: Senior Research Associate, Wellcome Trust Sanger Institute
2000-2004: Postdoctoral Fellow, University of Edinburgh
1996-2000: Research Scientist, Roslin Institute
Recent Publications
Feyder M, Karlsson RM, Mathur P, Lyman M, Bock R, Momenan R, Munasinghe J, Scattoni ML, Ihne J, Camp M,
et al. (2010). Association of mouse Dlg4 (PSD-95) gene deletion and human DLG4 gene variation with phenotypes relevant to autism spectrum disorders and Williams' syndrome. Am J Psychiatry 167, 1508-17.
Strathdee D, Whitelaw CB, Clark AJ (2008). Distal transgene insertion affects CpG island maintenance during differentiation. J Biol Chem. 283, 11509-15.
Strathdee D, Ibbotson H, Grant SG (2006). Expression of transgenes targeted to the Gt(ROSA)26Sor locus is orientation dependent. PLoS One 1, e4.
Komiyama NH, Watabe AM, Carlisle HJ, Porter K, Charlesworth P, Monti J, Strathdee DJ, O'Carroll CM, Martin SJ, Morris RG,
et al. (2002). SynGAP regulates ERK/MAPK signaling, synaptic plasticity, and learning in the complex with postsynaptic density 95 and NMDA receptor. J Neurosci. 22, 9721-32.
Lab Members
Scientific Officers: Laurence Cadalbert, Farah Naz Ghaffar